(RTTNews) - NewcelX Ltd. (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN), a clinical-stage immunology company with a focus on transplant medicine. It is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart or AT-1501, with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.
The company said the collaboration is anticipated to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility, supporting NewcelX's strategy to advance its clinical programs efficiently toward pivotal milestones.
NewcelX shares are currently trading at $2.9450, up 6.32%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
